AZD 4635

Drug Profile

AZD 4635

Alternative Names: AZD-4635; HTL 1071

Latest Information Update: 20 Jul 2016

Price : $50

At a glance

  • Originator Heptares Therapeutics
  • Developer AstraZeneca; Heptares Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Adenosine A2A receptor antagonists; Chemokine receptor antagonists; G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-small cell lung cancer; Solid tumours
  • Preclinical Cancer

Most Recent Events

  • 14 Jul 2016 CTP 270249 (NCT02740985) - updated patient no. and added FLS
  • 06 Jul 2016 Astrazeneca plans a phase II trial
  • 01 Jun 2016 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT02740985)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top